New York, January 23, 2026, 19:33 EST — After-hours
- Thermo Fisher (TMO) dropped 2.1% on Friday, ending its three-day winning streak
- Attention turns to the company’s January 29 earnings and guidance, while markets prepare for the Fed’s meeting next week
- Life-sciences tools peers slipped as well, suggesting a round of profit-taking within the sector
Shares of Thermo Fisher Scientific Inc (TMO) slipped 2.1% on Friday, settling at $625.98 after hitting a 52-week peak just the day before. The decline ended a three-day rally and occurred on higher-than-usual volume, while the broader market showed mixed results.
The pullback is significant as Thermo Fisher prepares to release its fourth-quarter and full-year 2025 earnings before the market opens on Thursday, Jan. 29. Management will field questions during a conference call at 8:30 a.m. ET. For those who bought into the recent rally, this report is a crucial test.
Markets enter this period with jitters still lingering. “It’s been a little bit of a short but steep roller-coaster ride,” said Yung-Yu Ma, chief investment strategist at PNC Financial Services Group, referring to the recent fluctuations in risk appetite. Reuters
The Federal Reserve is set to meet on Jan. 27-28, with its policy statement due at 2:00 p.m. ET on Wednesday, Jan. 28. A press conference will follow at 2:30 p.m. The decision will have implications for rate-sensitive growth stocks, particularly high-multiple healthcare tools firms.
Thermo Fisher’s decline wasn’t isolated. Waters and Danaher each fell roughly 2% on Friday, highlighting a pullback in the life-sciences tools sector even as the wider market held steady.
Thermo Fisher’s outlook earlier this month was notably positive. CEO Marc Casper highlighted a “very big focus on reshoring,” calling it a “tailwind in 2027 and 2028,” and noted an “improving set of end markets” as biotech funding picks up. Evercore ISI analyst Vijay Kumar described the tone as optimistic but said it didn’t “raise the bar for 2026.” Reuters
Investors are keenly awaiting updates on Thermo Fisher’s planned acquisition of clinical-trial data services provider Clario. The deal is expected to close by mid-2026, pending regulatory approvals. Any new details from management on the timeline or integration costs could shake a stock that’s been hovering near all-time highs.
Behind the headline figures, the Jan. 29 call will hinge on two straightforward questions: are biopharma clients increasing their purchases of tools and services, and is budget flexibility improving among smaller biotech firms? A change in order momentum—or in the company’s outlook for 2026—could swiftly shift investor sentiment.
The setup works both ways. If guidance disappoints or biotech funding stalls once more, the recent rally leaves little margin for mistakes. Any delays in closing deals or a cautious stance on pharma services demand could quickly challenge the stock’s gains.
Coming next: the Fed’s verdict drops Wednesday, Jan. 28. Then Thermo Fisher rolls out its quarterly results and guidance Thursday, Jan. 29, ahead of the open.
